Sunovion Announces FDA Acceptance for Review of New Drug Application for Dasotraline for the Treatment of ADHD

MLA

“Sunovion Announces FDA Acceptance for Review of New Drug Application for Dasotraline for the Treatment of ADHD.” Business Wire, 10 Nov. 2017. EBSCOhost, widgets.ebscohost.com/prod/customlink/proxify/proxify.php?count=1&encode=0&proxy=&find_1=&replace_1=&target=https://search.ebscohost.com/login.aspx?direct=true&site=eds-live&scope=site&db=edsggo&AN=edsgcl.514077739&authtype=sso&custid=ns315887.

APA

Sunovion Announces FDA Acceptance for Review of New Drug Application for Dasotraline for the Treatment of ADHD. (2017, November 10). Business Wire.

Chicago

Business Wire. 2017. “Sunovion Announces FDA Acceptance for Review of New Drug Application for Dasotraline for the Treatment of ADHD,” November 10. http://widgets.ebscohost.com/prod/customlink/proxify/proxify.php?count=1&encode=0&proxy=&find_1=&replace_1=&target=https://search.ebscohost.com/login.aspx?direct=true&site=eds-live&scope=site&db=edsggo&AN=edsgcl.514077739&authtype=sso&custid=ns315887.